EUCTR2009-010971-26-IT进行中（未招募）不适用
A Phase II trial comparing Brivudin 0.1% ophthalmic solution with Aciclovir 3 % ophthalmic ointment in the treatment of patients with herpetic dendritic keratitis - ND
MENARINI RICERCHE S.P.A.0 个研究点目标入组 50 人开始时间: 2009年9月30日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female Caucasian patients between 18 and 80 years of age. A female of childbearing potential may be enrolled providing she: has a negative pregnancy test at baseline and is routinely using a highly effective method of birth control resulting in a low failure rate (i.e. less than 1% per year); 2. Patients with clinically verified diagnosis of unilateral herpetic dendritic keratitis, either as primary episode or recurrence, showing all of the following: characteristic corneal lesions due to herpetic dendritic keratitis evidenced by fluorescein staining by slit lamp examination; onset of signs and symptoms less than 7 days preceding diagnosis/randomisation; 3. Able to give written informed consent before any study related procedure; 4. Able to attend all the visits scheduled in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients with any stromal infiltrations/lesions, anterior chamber involvement, or any affection of deeper structures of the eye (e.g. keratouveitis); 2. Patients suffering from any disease limiting eye lid closure function such as eye lid deformities, exophthalmus, facial palsy; 3. Patients with bilateral herpetic keratitis; 4. Patients with any corneal or conjunctival bacterial superinfection of the affected eye; 5. Patients with a visual acuity of the contralateral, unaffected eye of 6/60 (20/200) or less; 6. Patients with an intraocular pressure > 30 mmHg in the affected eye ; 7. Patients having received local antiherpetic treatment (local antivirals and/or local steroids) within 8 weeks prior to study entry; 8. Patients who received systemic antiviral therapy within 1 month prior to study entry; 9. Patients under immunosuppressive therapy, including continuous treatment with systemic steroids; 10. Patients who underwent tissue transplantation (e.g. amniotic membrane transplantation or keratoplasty [PKP]); 11. Patients with a history of recurrences of epithelial herpetic keratitis known to be caused by HSV-2; 12. Patients with a history of hypersensitivity to aciclovir; 13. Patients with a history of hypersensitivity to brivudin; 14. Patients with known HIV infection; 15. Patients treated and/or planned to be treated with any 5-fluoropyrimidines (e.g. 5-FU, tegafur, capecitabin, or flucytosin) within 1 month prior to study entry and/or after study entry; 16. Patients with any serious intercurrent illness which, in the opinion of the Investigator, is incompatible with the protocol (e.g. systemic infections, sepsis, severe atopic diseases, malignant diseases); 17. Pregnant or breast feeding women; 18. Patients who received any other investigational agent within 30 days prior to study entry; 19. Patients not suitable for adequate follow up.
研究者
相似试验
进行中（未招募）
不适用
A Phase II trial comparing Brivudin 0.1% ophthalmic solution with Aciclovir 3 % ophthalmic ointment in the treatment of patients with herpetic dendritic keratitisEUCTR2009-010971-26-DEMenarini Ricerche S.p.A.50
已完成
2 期
Dry Eye Disease Study With BrimonidineDry EyeNCT03418727Ocugen84
已完成
3 期
Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular HypertensionGlaucomaOcular HypertensionNCT00652483Allergan433
已完成
3 期
Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular RednessHyperemiaNCT01959230Bausch & Lomb Incorporated60
Unknown
4 期
Comparison of Efficacy and Ocular Surface Disease Assessment Between BRIDIN-T Eye Drops 0.15% and ALPHAGAN-P Eye Drops 0.15% in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized, Multi-center TrialGlaucomaOcular HypertensiveNCT04647461CHA University61